SG11201805532XA - Multivalent and multispecific 41bb-binding fusion proteins - Google Patents
Multivalent and multispecific 41bb-binding fusion proteinsInfo
- Publication number
- SG11201805532XA SG11201805532XA SG11201805532XA SG11201805532XA SG11201805532XA SG 11201805532X A SG11201805532X A SG 11201805532XA SG 11201805532X A SG11201805532X A SG 11201805532XA SG 11201805532X A SG11201805532X A SG 11201805532XA SG 11201805532X A SG11201805532X A SG 11201805532XA
- Authority
- SG
- Singapore
- Prior art keywords
- suite
- jolla
- california
- sdab
- pines road
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 abstract 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 abstract 6
- 235000008331 Pinus X rigitaeda Nutrition 0.000 abstract 2
- 235000011613 Pinus brutia Nutrition 0.000 abstract 2
- 241000018646 Pinus brutia Species 0.000 abstract 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract 2
- 101150093335 KIN1 gene Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277028P | 2016-01-11 | 2016-01-11 | |
| PCT/US2017/013040 WO2017123650A2 (en) | 2016-01-11 | 2017-01-11 | Multivalent and multispecific 41bb-binding fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805532XA true SG11201805532XA (en) | 2018-07-30 |
Family
ID=59275541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912405TA SG10201912405TA (en) | 2016-01-11 | 2017-01-11 | Multivalent and multispecific 41bb-binding fusion proteins |
| SG11201805532XA SG11201805532XA (en) | 2016-01-11 | 2017-01-11 | Multivalent and multispecific 41bb-binding fusion proteins |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912405TA SG10201912405TA (en) | 2016-01-11 | 2017-01-11 | Multivalent and multispecific 41bb-binding fusion proteins |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10501551B2 (de) |
| EP (1) | EP3402823A4 (de) |
| JP (3) | JP7022993B2 (de) |
| KR (1) | KR20180096789A (de) |
| CN (1) | CN108779176A (de) |
| AU (2) | AU2017207742B2 (de) |
| BR (1) | BR112018013677A2 (de) |
| CA (1) | CA3009661A1 (de) |
| IL (2) | IL260530B2 (de) |
| MX (2) | MX2018008308A (de) |
| SG (2) | SG10201912405TA (de) |
| WO (1) | WO2017123650A2 (de) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014029883B1 (pt) | 2012-05-31 | 2023-10-24 | Sorrento Therapeutics Inc. | Anticorpo recombinante anti-pd-l1 e uso de um anticorpo recombinante anti-pd-l1 |
| TW201831513A (zh) | 2016-06-20 | 2018-09-01 | Ｆ星貝塔有限公司 | 結合物件(一) |
| ES2858091T3 (es) | 2016-06-20 | 2021-09-29 | F Star Therapeutics Ltd | Moléculas de unión que se unen a PD-L1 y LAG-3 |
| CN109641960A (zh) | 2016-06-29 | 2019-04-16 | 检查点治疗公司 | Pd-l1特异性抗体及使用其的方法 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| EP3512875A2 (de) | 2016-09-15 | 2019-07-24 | Quadrucept Bio Limited | Multimere, tetramere und oktamere |
| EA201990578A1 (ru) * | 2016-09-23 | 2019-10-31 | Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой | |
| JP7183163B2 (ja) | 2017-01-06 | 2022-12-05 | クレシェンド・バイオロジックス・リミテッド | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 |
| BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| CA3058477A1 (en) | 2017-04-11 | 2018-10-18 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| KR102629972B1 (ko) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| CA3071211A1 (en) * | 2017-08-04 | 2019-02-07 | Genmab A/S | Binding agents binding to pd-l1 and cd137 and use thereof |
| JP2020531438A (ja) * | 2017-08-16 | 2020-11-05 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、およびｅｇｆｒ、ｈｌａ−ｅ、ｃｃｒ４、またはｐｄ−ｌ１に結合するタンパク質 |
| EP3470429A1 (de) * | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Auf pdl1 gerichtete antikörper und verfahren zur verwendung davon |
| EP3470426A1 (de) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispezifischer antikörper |
| JP7442443B2 (ja) | 2017-10-10 | 2024-03-04 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 多重特異性抗体 |
| JP2021501569A (ja) * | 2017-10-10 | 2021-01-21 | ヌマブ セラピューティックス アーゲー | Ｐｄｌ１を標的とする抗体及びそれを用いる方法 |
| KR20200083574A (ko) * | 2017-11-13 | 2020-07-08 | 크레센도 바이오로직스 리미티드 | Cd137 및 psma에 결합하는 분자 |
| AU2018366650A1 (en) * | 2017-11-17 | 2020-05-21 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against PD-L1 |
| WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
| CN109970860A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
| WO2019129644A1 (en) * | 2017-12-28 | 2019-07-04 | Julius-Maximilians-Universität Würzburg | TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA) |
| TW201938196A (zh) * | 2018-01-18 | 2019-10-01 | 美商南特生物科學股份有限公司 | 融合蛋白擴展 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| CA3093387A1 (en) | 2018-03-08 | 2019-09-12 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating cancer and infectious diseases |
| EP3774918A4 (de) * | 2018-03-27 | 2022-04-06 | Systimmune, Inc. | Verfahren zur herstellung und verwendung von anleitungs- und navigationssteuerproteinen |
| CN112399973B (zh) * | 2018-06-05 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
| TW202035447A (zh) * | 2018-07-04 | 2020-10-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎雙特異性促效性4-1bb抗原結合分子 |
| JP7360440B2 (ja) | 2018-07-12 | 2023-10-12 | エフ－スター セラピューティクス リミテッド | Ｐｄ－ｌ１及びｃｄ１３７に結合する抗体分子 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| TW202035451A (zh) | 2018-07-24 | 2020-10-01 | 美商英伊布里克斯公司 | 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法 |
| FI3830120T3 (fi) * | 2018-07-31 | 2023-06-13 | Pieris Pharmaceuticals Gmbh | CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini |
| TWI839395B (zh) * | 2018-10-09 | 2024-04-21 | 瑞士商Ｎｕｍａｂ治療公司 | 靶向cd137的抗體及其使用方法 |
| WO2020076970A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| TW202028245A (zh) | 2018-10-11 | 2020-08-01 | 美商英伊布里克斯公司 | Dll3單域抗體及其治療性組合物 |
| AU2019356573A1 (en) | 2018-10-11 | 2021-05-27 | Inhibrx Biosciences, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
| TW202021986A (zh) | 2018-10-11 | 2020-06-16 | 美商英伊布里克斯公司 | 5t4單域抗體及其治療性組合物 |
| KR20210099052A (ko) | 2018-11-30 | 2021-08-11 | 에이비엘바이오 주식회사 | 항-pd-l1/항-4-1bb 이중특이적 항체 및 이의 용도 |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| EP3986933A1 (de) * | 2019-06-21 | 2022-04-27 | Regeneron Pharmaceuticals, Inc. | Verwendung von bispezifischen antigenbindenden molekülen, die psma und cd3 binden, in kombination mit 4-1bb-co-stimulation |
| CN118791614A (zh) * | 2019-06-26 | 2024-10-18 | 圆祥生技股份有限公司 | T细胞活化抗体 |
| EP4041772A4 (de) * | 2019-10-11 | 2024-04-24 | Nanjing Leads Biolabs Co., Ltd. | 4-1bb-bindende antikörper und verwendungen davon |
| EP3816185A1 (de) | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispezifischer antikörper gegen pd-l1 und ein tumorassoziiertes antigen |
| WO2021140130A1 (en) * | 2020-01-09 | 2021-07-15 | F. Hoffmann-La Roche Ag | New 4-1bbl trimer-containing antigen binding molecules |
| JP2023513896A (ja) * | 2020-02-04 | 2023-04-04 | ジェンマブ エー／エス | 療法において使用するための抗体 |
| AU2021237513B2 (en) * | 2020-03-20 | 2024-08-15 | Remegen Co., Ltd. | Bispecific fusion protein and application thereof |
| WO2021190980A1 (en) | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimers for viral strain evolution |
| CN113461824A (zh) * | 2020-03-31 | 2021-10-01 | 普米斯生物技术(珠海)有限公司 | 一种构建多特异性抗体的平台 |
| JP2023531042A (ja) * | 2020-06-30 | 2023-07-20 | 諾納生物（蘇州）有限公司 | ４－１ｂｂ結合タンパク質及びその用途 |
| JP2023531672A (ja) | 2020-06-30 | 2023-07-25 | ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド | Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質 |
| CN114195900B (zh) | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
| EP3988568A1 (de) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Kombinationsbehandlung |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| WO2022184659A1 (en) | 2021-03-01 | 2022-09-09 | Quadrucept Bio Limited | Antibody domains & multimers |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| WO2023146394A1 (en) * | 2022-01-25 | 2023-08-03 | Merus N.V. | Combination therapy for the treatment of cancer |
| KR20240144422A (ko) | 2022-03-15 | 2024-10-02 | 컴퓨젠 엘티디. | 암 치료의 단독치료법 및 병용치료법에서 il-18bp 길항제 항체 및 이의 용도 |
| WO2023205793A2 (en) * | 2022-04-22 | 2023-10-26 | Inhibrx, Inc. | Siglec-8 binding proteins and uses thereof |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003302118A1 (en) | 2002-05-10 | 2004-06-15 | Epitome Biosystems, Inc. | Unique recognition sequences and methods of use thereof in protein analysis |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| EP2495257A3 (de) | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung |
| EP2468765B1 (de) | 2006-03-03 | 2015-04-22 | ONO Pharmaceutical Co., Ltd. | Tetramer der extrazelluläre Domäne des PD-L1 |
| US20080108070A1 (en) | 2006-09-08 | 2008-05-08 | Corixa Corporation | Methods, compositions, and kits for the detection and monitoring of colon cancer |
| US8907065B2 (en) | 2006-12-15 | 2014-12-09 | Ablynx N.V. | Polypeptides that modulate the interaction between cells of the immune system |
| CA2616144A1 (en) * | 2007-09-10 | 2009-03-10 | Commonwealth Scientific And Industrial Research Organisation | Insect olfactory receptors and ligands therefor |
| WO2010007376A2 (en) | 2008-07-18 | 2010-01-21 | Domantis Limited | Compositions monovalent for cd28 binding and methods of use |
| CN102245640B (zh) | 2008-12-09 | 2014-12-31 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| US20110262348A1 (en) * | 2010-03-29 | 2011-10-27 | Vrije Universiteit Brussel | Selective targeting of intratumoral cells |
| CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| NZ714128A (en) * | 2010-09-09 | 2017-10-27 | Pfizer | 4-1bb binding molecules |
| WO2012088461A2 (en) | 2010-12-23 | 2012-06-28 | Biogen Idec Inc. | Linker peptides and polypeptides comprising same |
| EP2890715B1 (de) * | 2012-08-03 | 2020-12-16 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1- und pd-l2-doppelbindende antikörper in form eines einzelnen wirkstoffes und verfahren zur verwendung |
| WO2014028776A1 (en) * | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| WO2014116846A2 (en) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| CN106999583A (zh) | 2014-11-17 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法 |
| CN114702586A (zh) | 2015-03-13 | 2022-07-05 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CA3047059A1 (en) | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
-
2017
- 2017-01-11 MX MX2018008308A patent/MX2018008308A/es unknown
- 2017-01-11 KR KR1020187022340A patent/KR20180096789A/ko unknown
- 2017-01-11 EP EP17738869.1A patent/EP3402823A4/de active Pending
- 2017-01-11 WO PCT/US2017/013040 patent/WO2017123650A2/en active Application Filing
- 2017-01-11 CN CN201780005185.7A patent/CN108779176A/zh active Pending
- 2017-01-11 JP JP2018535301A patent/JP7022993B2/ja active Active
- 2017-01-11 US US15/404,016 patent/US10501551B2/en active Active
- 2017-01-11 IL IL260530A patent/IL260530B2/en unknown
- 2017-01-11 SG SG10201912405TA patent/SG10201912405TA/en unknown
- 2017-01-11 SG SG11201805532XA patent/SG11201805532XA/en unknown
- 2017-01-11 CA CA3009661A patent/CA3009661A1/en active Pending
- 2017-01-11 IL IL304871A patent/IL304871A/en unknown
- 2017-01-11 BR BR112018013677A patent/BR112018013677A2/pt unknown
- 2017-01-11 AU AU2017207742A patent/AU2017207742B2/en active Active
-
2018
- 2018-07-04 MX MX2024007711A patent/MX2024007711A/es unknown
-
2019
- 2019-10-15 US US16/601,825 patent/US11566078B2/en active Active
-
2022
- 2022-02-01 JP JP2022013954A patent/JP7510447B2/ja active Active
- 2022-02-11 AU AU2022200918A patent/AU2022200918A1/en active Pending
- 2022-12-16 US US18/067,484 patent/US20230416387A1/en active Pending
-
2024
- 2024-06-21 JP JP2024100203A patent/JP2024123158A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170198050A1 (en) | 2017-07-13 |
| IL304871A (en) | 2023-10-01 |
| EP3402823A4 (de) | 2019-09-18 |
| BR112018013677A2 (pt) | 2019-01-22 |
| IL260530A (de) | 2018-08-30 |
| IL260530B1 (en) | 2023-09-01 |
| RU2018128601A (ru) | 2020-02-13 |
| IL260530B2 (en) | 2024-01-01 |
| RU2018128601A3 (de) | 2020-06-17 |
| US20230416387A1 (en) | 2023-12-28 |
| CA3009661A1 (en) | 2017-07-20 |
| EP3402823A2 (de) | 2018-11-21 |
| US11566078B2 (en) | 2023-01-31 |
| JP2019504831A (ja) | 2019-02-21 |
| JP2022062146A (ja) | 2022-04-19 |
| AU2017207742A1 (en) | 2018-07-12 |
| JP7022993B2 (ja) | 2022-02-21 |
| US10501551B2 (en) | 2019-12-10 |
| AU2022200918A1 (en) | 2022-03-03 |
| WO2017123650A2 (en) | 2017-07-20 |
| CN108779176A (zh) | 2018-11-09 |
| KR20180096789A (ko) | 2018-08-29 |
| MX2024007711A (es) | 2024-07-01 |
| SG10201912405TA (en) | 2020-02-27 |
| AU2017207742B2 (en) | 2022-03-17 |
| JP7510447B2 (ja) | 2024-07-03 |
| JP2024123158A (ja) | 2024-09-10 |
| MX2018008308A (es) | 2019-05-15 |
| US20200199243A1 (en) | 2020-06-25 |
| WO2017123650A3 (en) | 2017-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805532XA (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201809336QA (en) | Anti-pd-l1 antibodies | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201901550WA (en) | Method and apparatus for data processing | |
| SG11201809041TA (en) | Compositions and methods for selective protein expression | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201811490XA (en) | Cd3 binding antibodies | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
| SG11201806709PA (en) | Universal tokenisation system for blockchain-based cryptocurrencies | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201804856VA (en) | C-terminal lysine conjugated immunoglobulins | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201805493YA (en) | Binding members with altered diversity scaffold domains | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| SG11201807474SA (en) | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |